Advances in experimental medicine and biology, Год журнала: 2024, Номер unknown, С. 55 - 69
Опубликована: Янв. 1, 2024
Язык: Английский
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(13), С. 7226 - 7226
Опубликована: Июнь 30, 2024
Breast cancer represents the most prevalent form of and leading cause cancer-related mortality among females worldwide. It has been reported that several risk factors contribute to appearance progression this disease. Despite advancements in breast treatment, a significant portion patients with distant metastases still experiences no cure. The extracellular matrix potential target for enhanced serum biomarkers cancer. Furthermore, degradation epithelial–mesenchymal transition constitute primary stages local invasion during tumorigenesis. Additionally, microbiome influence on diverse physiological processes. is emerging microbial dysbiosis element development various cancers, including Thus, better understanding interactions could provide novel alternatives treatment management. In review, we summarize current evidence regarding intricate relationship between microbiome. We discuss arising associations future perspectives field.
Язык: Английский
Процитировано
9
Biomedicines, Год журнала: 2025, Номер 13(1), С. 100 - 100
Опубликована: Янв. 3, 2025
The gut microbiota, a dynamic ecosystem of trillions microorganisms, produces secondary metabolites that profoundly influence host health. Recent research has highlighted the significant role these metabolites, particularly short-chain fatty acids, indoles, and bile in modulating immune responses, impacting epigenetic mechanisms, contributing to disease processes. In gastrointestinal (GI) cancers such as colorectal, liver, gastric cancer, microbial can drive tumorigenesis by promoting inflammation, DNA damage, evasion. Conversely, same hold therapeutic promise, potentially enhancing responses chemotherapy immunotherapy even directly suppressing tumor growth. addition, play crucial roles infectious susceptibility resilience, mediating pathways impact pathogen resistance. By consolidating recent insights into microbiota's shaping health, this review underscores potential targeting microbiome-derived for treating GI diseases calls further microbiome-based interventions.
Язык: Английский
Процитировано
1
Biomedicines, Год журнала: 2025, Номер 13(2), С. 422 - 422
Опубликована: Фев. 10, 2025
The intricate relationship between anticancer drugs and the gut microbiome influences cancer treatment outcomes. This review paper focuses on role of integrity in enhancing efficacy safety drug therapy, emphasizing pharmacokinetic interactions microbiota. It explores how disruptions to composition, or dysbiosis, can alter metabolism, immune responses, side effects. By examining mechanisms disruption caused by drugs, this highlights specific case studies like cyclophosphamide, 5-fluorouracil, irinotecan, their impact microbial diversity clinical also discusses microbiome-targeted strategies, including prebiotics, probiotics, postbiotics, fecal microbiota transplantation (FMT), as promising interventions enhance treatment. Furthermore, potential profiling personalizing therapy integrating these into practice is explored. Finally, proposes future research directions, developing novel biomarkers a deeper comprehension drug-microbiome interactions, respond current gaps knowledge improve patient outcomes care.
Язык: Английский
Процитировано
1
Clinical & Translational Oncology, Год журнала: 2024, Номер unknown
Опубликована: Июнь 18, 2024
Abstract Breast cancer (BC) is one of the most diagnosed cancers in women. Based on histological characteristics, they are classified as non-invasive, or situ (tumors located within milk ducts lobules) and invasive. BC may develop from carcinomas over time. Determining prognosis predicting response to treatment essential tools manage this disease reduce its incidence mortality, well promote personalized therapy for patients. However, half cases not associated with known risk factors. In addition, some patients resistance relapse. Therefore, it necessary identify new biomarkers strategies that improve existing therapies. regard, role microbiome being researched could play a carcinogenesis efficacy This review aims describe specific patterns BC. For this, literature search was carried out PubMed database using MeSH terms “Breast Neoplasms” “Gastrointestinal Microbiome”, including 29 publications. Most studies have focused characterizing gut breast tissue Likewise, animal models vitro investigated impact microbiota (GM) treatments effects tumor cells were included. results included articles, be an imbalance GM. varied depending molecular type, stage grade cancer, menopause, menarche, body mass index, physical activity. microbial profile identified biomarker. On other hand, suggest GM influence microorganisms bacterial metabolites therapies development.
Язык: Английский
Процитировано
5
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(19), С. 10255 - 10255
Опубликована: Сен. 24, 2024
Hematologic malignancies (HMs), including leukemia, lymphoma, and multiple myeloma, involve the uncontrolled proliferation of abnormal blood cells, posing significant clinical challenges due to their heterogeneity varied treatment responses. Despite recent advancements in therapies that have improved survival rates, particularly chronic lymphocytic leukemia acute lymphoblastic treatments like chemotherapy stem cell transplantation often disrupt gut microbiota, which can negatively impact outcomes increase infection risks. This review explores complex, bidirectional interactions between microbiota cancer patients with HMs. Gut influence drug metabolism through mechanisms such as production enzymes bacterial β-glucuronidases, alter efficacy toxicity. Moreover, microbial metabolites short-chain fatty acids modulate host immune response, enhancing effectiveness. However, therapy reduces diversity beneficial bacteria, Bifidobacterium Faecalibacterium, while increasing pathogenic bacteria Enterococcus Escherichia coli. These findings highlight critical need preserve during treatment. Future research should focus on personalized microbiome-based therapies, probiotics, prebiotics, fecal transplantation, improve quality life for hematologic malignancies.
Язык: Английский
Процитировано
4
Gut Microbes Reports, Год журнала: 2025, Номер 2(1), С. 1 - 23
Опубликована: Апрель 9, 2025
Язык: Английский
Процитировано
0
Cancers, Год журнала: 2024, Номер 16(21), С. 3671 - 3671
Опубликована: Окт. 30, 2024
The gut microbiome has emerged as a crucial player in modulating cancer therapies, including radiotherapy. In the case of breast cancer, interplay between and radiotherapy-derived metabolites may enhance therapeutic outcomes minimize adverse effects. this review, we explore bidirectional relationship cancer. We explain how composition influences progression treatment response, its treatments influence composition. A dual role for is explored article, highlighting both their benefits potential hazards. By integrating genomics, metabolomics, bioinformatics tools, present comprehensive overview these interactions. study provides real-world insight through studies clinical trials, while innovations such probiotics, dietary interventions are examined to modulate effectiveness. Moreover, ethical considerations patient perspectives discussed, ensuring understanding subject. Towards revolutionizing strategies improving outcomes, review concludes with future research directions. It also envisions metabolite into personalized therapy.
Язык: Английский
Процитировано
3
Molecules, Год журнала: 2024, Номер 29(13), С. 3073 - 3073
Опубликована: Июнь 27, 2024
The microbiome is capable of modulating the bioavailability chemotherapy drugs, mainly due to metabolizing these agents. Multiple cytostatic bacterial metabolites were recently identified that have effects on cancer cells. In this study, we addressed question whether a set (cadaverine, indolepropionic acid and indoxylsulfate) can interfere with agents used in management breast (doxorubicin, gemcitabine, irinotecan, methotrexate, rucaparib, 5-fluorouracil paclitaxel). drugs applied wide concentration range which metabolite was added within its serum reference range, cell proliferation assessed. There no interference between methotrexate or rucaparib metabolites. Nevertheless, cadaverine modulated Hill coefficient inhibitory curve doxorubicin 5-fluorouracil. Changes implicate alterations kinetics binding their targets. These an unpredictable significance from clinical pharmacological perspective. Importantly, decreased IC50 value paclitaxel, potentially advantageous combination.
Язык: Английский
Процитировано
2
Brain Sciences, Год журнала: 2024, Номер 14(10), С. 974 - 974
Опубликована: Сен. 27, 2024
Alzheimer's disease is a progressive neurodegenerative characterized by structural changes in the brain, including hippocampal atrophy, cortical thinning, amyloid plaques, and tau tangles. Due to aging of global population, burden expected increase, making exploration non-pharmacological interventions, such as physical exercise, an urgent priority.
Язык: Английский
Процитировано
1
Frontiers in Cellular and Infection Microbiology, Год журнала: 2024, Номер 14
Опубликована: Ноя. 21, 2024
As a complicated and heterogeneous condition, breast cancer (BC) has posed tremendous public health challenge across the world. Recent studies have uncovered crucial effect of human microbiota on various perspectives disease, which include cancer. The oral-gut microbiome axis, particularly, been implicated in occurrence development colorectal through their intricate interactions with host immune system modulation systemic inflammation. However, research concerning impact axis BC remains scarce. This study focused comprehensively reviewing summarizing latest ideas about potential bidirectional relation gut oral BC, emphasizing tumorigenesis, treatment response, overall patient outcomes. review can reveal prospect tumor microecology propose novel viewpoint that be breakthrough point future studies.
Язык: Английский
Процитировано
0